Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

acute myeloid leukemia and myelodysplastic syndromes related to topoisomerase type 2 inhibitor - Clinical Profile, Genes & Research | Kisho | Kisho

Rare Disease

acute myeloid leukemia and myelodysplastic syndromes related to topoisomerase type 2 inhibitor

MONDO:0015165

Also known as:AML and myelodysplastic syndromes related to topoisomerase type 2 inhibitor

Overview

Acute myeloid leukemia and myelodysplastic syndromes related to topoisomerase type 2 inhibitor represent a subgroup of therapy-related myeloid neoplasms (t-MN), associated with treatment of an unrelated neoplastic disease with cytotoxic agents, like etoposid, doxorubicin, daunorubicin and others. The neoplastic cells often show rearrangements involving the mixed lineage leukemia gene at 11q23. This subgroup of t-MN is typically associated with overt leukemia, without preceding myelodysplastic syndrome, developing 2-3 years after exposure, presenting with non-specific symptoms related to ineffective hematopoesis (fatigue, bleeding and bruising, recurrent infections, bone pain) and/or extramedullary site involvement.

ResearchLimited published research (3 articles)

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

No clinical trials have been registered for acute myeloid leukemia and myelodysplastic syndromes related to topoisomerase type 2 inhibitor.

3 publications have been identified in PubMed for acute myeloid leukemia and myelodysplastic syndromes related to topoisomerase type 2 inhibitor. Research spans Review / Meta-Analysis (33%), Case Report / Case Series (33%), and Epidemiology / Natural History (33%).

Recent Publications

Fawzy M (2025). [PMID: 40397208](https://pubmed.ncbi.nlm.nih.gov/40397208/). *Discover oncology*. [Epidemiology / Natural History]
Alkhaledi A (2025). [PMID: 41363702](https://pubmed.ncbi.nlm.nih.gov/41363702/). *Cancer reports (Hoboken, N.J.)*. [Case Report / Case Series]
Guilatco AJ (2024). [PMID: 39072049](https://pubmed.ncbi.nlm.nih.gov/39072049/). *Journal of bone oncology*. [Review / Meta-Analysis]

Data assembled from 3 of 12 sources · Last updated Sep 18, 2026, 3:57 AM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Patient Support

Financial & Access Support (External Programs)

View all programs →

Acute Myeloid Leukemia Fund

Premium/CopayCurrently AcceptingOperated by HealthWell Foundation

Visit official site

Program availability and eligibility requirements are set by each foundation. Contact them directly to learn more about your options.

Are you a patient organization for this condition?

Claim this page and your organization will be listed here for patients and families to find.

Be recognized as the official organization
Get notified of new trials, FDA decisions, and research
Appear in the disease page directory
Embed this content on your website — free

Medical References

External Resources

Orphanet

European rare disease database

Orphanet:102381

GARD

Genetic and Rare Diseases Info Center

GARD:19836

Questions for Your Care Team

→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

acute myeloid leukemia and myelodysplastic syndromes related to topoisomerase type 2 inhibitor

Overview

Research Landscape

Recent Publications

Patient Support

Financial & Access Support (External Programs)

Are you a patient organization for this condition?

Medical References

External Resources

Orphanet

GARD

Related Diseases

Questions for Your Care Team

Questions for Your Care Team